Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies.
Saved in:
| Title: | Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies. |
|---|---|
| Authors: | McDorman, Kevin S.1 (AUTHOR) kevin.mcdorman@crl.com, Bennet, Bindu M.2 (AUTHOR), Colman, Karyn3 (AUTHOR), Fikes, James D.4 (AUTHOR), Keirstead, Natalie D.5 (AUTHOR), Lanning, Lynda6 (AUTHOR), Munch, Barbara7 (AUTHOR), Romeike, Annette8 (AUTHOR), Schafer, Kenneth A.9 (AUTHOR), Schorsch, Frédéric10 (AUTHOR), Thibodeau, Michael S.11 (AUTHOR), Thomas, Heath C.12 (AUTHOR), Troth, Sean13 (AUTHOR), Vahle, John L.14 (AUTHOR), Geoly, Frank J.15 (AUTHOR) |
| Source: | Toxicologic Pathology. Feb2024, Vol. 52 Issue 2/3, p138-148. 11p. |
| Database: | Environment Complete |
Be the first to leave a comment!
